Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Millennium Pharmaceuticals, Inc
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Brentuximab vedotin+Adriamycin, vinblastine, and dacarbazine in pediatric patients with advanced stage newly diagnosed Hodgkin lymphoma Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Phase 1 Primary Objective: To assess the safety and tolerability, and to identify the recommended dose of brentuximab vedotin when combined with multiagent chemotherapy regimen AVD for first-line tr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate
This is the first study of MLN3897 in any disease population. It seeks to establish: • The ability of MLN3897 to modify the signs and symptoms of rheumatoid arthritis (RA) • The safety and tolerabilit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
MAJ Il y a 4 ans
The aim of the study is to provide patients with certain kinds of cancer continued access to the same drug they have received in a previous study, if they have benefited from the use of the drug. El objetivo de este estudio seguir ofreciendo a los pacientes acceso al mismo medicamento que han venido recibiendo en un estudio previo, si han tenido beneficio del uso del medicamento
Primary Objective: To provide continued access of ixazomib and to evaluate the long-term safety profile of ixazomib. Objetivo Principal: Seguir ofreciendo acceso a ixazomib y evaluar la segurida...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3